Best Practices for Applying HDX-MS to FBLD

Why It Matters

HDX‑MS now proves viable for characterizing millimolar‑affinity fragments, expanding the biophysical toolkit for early‑stage drug discovery and enabling structural insight where crystallography or NMR may be impractical.

Key Takeaways

• HDX‑MS detects binding of millimolar‑affinity fragments.
• Optimal protein concentration: 10 µM yields most peptides.
• Sub‑stoichiometric occupancy (≈18%) sufficient for reliable signal.
• pH shift to 9 reveals hidden proline‑pocket binding.
• HDX‑MS complements crystallography, but offers lower resolution.

Pulse Analysis

Hydrogen‑deuterium exchange mass spectrometry has long been a niche technique in fragment‑based lead discovery (FBLD) due to its sensitivity limits. The new open‑access paper from iBET‑Instituto and Merck revisits this perception by systematically applying HDX‑MS to Cyclophilin D fragments with affinities in the low‑millimolar range. By selecting a protein concentration of 10 µM—the point at which peptide coverage peaked—the researchers maximized detectable exchange events, allowing even 5‑percent occupancy to generate statistically significant protection patterns. This methodological rigor addresses the historic challenge of low‑occupancy ligands, showing that careful experimental design can overcome inherent sensitivity constraints.

The study also highlights practical adjustments that sharpen HDX‑MS readouts. Testing fragments at 2.5, 5, and 10 mM revealed consistent deuterium uptake reductions, confirming that sub‑stoichiometric binding is sufficient for reliable detection. Statistical filters were employed to differentiate true protection from noise, and a pH increase from 7.4 to 9 uncovered binding in the proline pocket that remained invisible at physiological pH. These findings underscore the importance of buffer conditions and data‑analysis pipelines when interpreting weak‑binder data, offering a reproducible workflow for other laboratories seeking to adopt HDX‑MS in early‑stage screening.

From a strategic perspective, the ability to map fragment binding sites without crystallography accelerates hit validation and prioritization, especially for targets that are difficult to crystallize. While HDX‑MS does not match the atomic resolution of X‑ray or protein‑detected NMR, its speed, low sample consumption, and compatibility with solution‑phase dynamics make it a valuable complementary tool. The paper’s open‑access status and detailed protocol encourage broader adoption, potentially reshaping how medicinal chemists integrate biophysical methods into fragment‑based campaigns and paving the way for hybrid approaches that combine HDX‑MS with high‑resolution structural techniques.